News - BioSpace
This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that characterizes this space.
BioSpace: Biotech, Pharmaceutical and Clinical Research News
Dec 11, 2010 · GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment model; Eli Lilly and Novo Nordisk pump new funds into manufacturing; and AbbVie makes a Cerevel comeback while uniQure clears a path toward accelerated approval in Huntington’s disease.
CRO Javara Cuts Staff as It Restructures - BioSpace
5 days ago · June 27. EuroAPI, a spinoff of Sanofi, will lay off approximately 550 people by 2027, the company announced Wednesday. The cuts are part of a multi-year restructuring plan that EuroAPI first made public when it unveiled its 2023 results, though few details were given at the time.According to the Wednesday announcement, the manufacturer will sell plants in Haverhill, UK, and Brindisi, Italy ...
Join Our Team - BioSpace
BioSpace is the digital hub for life sciences news and jobs. Our mission is to provide essential insights, tools, and opportunities to connect the innovative organizations and talented professionals who advance health and quality of life across the globe.
ESSENCE Phase 3 trial results demonstrating statistically
The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed …
AusperBio to Present Ongoing AHB-137 Clinical Data in Late
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced that new clinical data from its lead candidate AHB-137, an antisense oligonucleotide (ASO) therapeutic, will be featured in a late-breaking oral presentation at the 2024 Liver Meeting ®, organized by the American ...
Big Pharma’s Interest Grows in Evolving Cell and Gene ... - BioSpace
Oct 9, 2024 · In welcome remarks at the conference on Monday, Alliance for Regenerative Medicine (ARM) CEO Tim Hunt said there has been uptick in investment in cell and gene therapies in 2024, noting that 13 of the 15 largest pharma companies by market capitalization have an “active presence” in the sector.. Hunt said many leading Big Pharma companies—including Astellas, Bayer, BMS, Eli Lilly, Gilead ...
Novo Makes Case to FDA That Semaglutide Is Too Complex for
Oct 23, 2024 · Novo Nordisk is asking the FDA to stop compounding pharmacies from making altered versions of its blockbuster obesity treatment semaglutide, citing the “demonstrable difficulty” of safely producing the drug.. In filings, which the agency posted on its website on Tuesday, Novo nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding (DDC) list, which ...
COVID-19 Critic Marty Makary Is Trump’s Likely Pick for ... - BioSpace
Nov 21, 2024 · Johns Hopkins surgeon Martin Makary is the leading pick for the top FDA position in President-elect Donald Trump’s incoming administration, according to several media reports on Wednesday.
Lilly’s Tirzepatide Could Land Again on FDA Drug Shortage
Oct 14, 2024 · The FDA on Friday announced that it would reconsider taking Eli Lilly ’s type 2 diabetes and weight loss medication tirzepatide off its shortage list, a decision that could allow compounded versions of the drug back into the market, according to media reports.. The regulator in a court filing said that it would conduct another review to better assess the supply status of tirzepatide and more ...